Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration

NCT06973564 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06973564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 29, 2025
Completion date
February 29, 2028
Enrollment
294 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors